Congestive heart failure has become a major worldwide public health problem among the aging population. More than two per cent of population of the western world has heart failure. Every year, half a million new patients in the USA and more than 50,000 new patients in Nordic countries are diagnosed with cardiac failure. There is a demand for new treatments for congestive heart failure. Our understanding of the pathophysiological mechanisms of heart failure has improved and we know more than ever about the impact of neurohumoral pathways, remodelling, myocardial ischemia, infarction, and atrial and ventricular arrhythmias. Despite significant improvements in the medical management of this condition, patients are repeatedly readmitted for care and most patients die within three years of diagnosis.
